Table 3.
Current Breakpoint Usage by Laboratory Location (United States Versus International)
| Organism | Antimicrobial Agent | United States | International | P Value, Difference Between US and International | ||
|---|---|---|---|---|---|---|
| Total No. of Laboratories | Current Breakpoints, No. (%) | Total No. of Laboratories | Current Breakpoints, No. (%) | |||
| Enterobacterales | Ceftazidime | 1046 | 620 (59.3) | 201 | 164 (81.6) | <.001 |
| Enterobacterales | Ceftriaxone | 1124 | 694 (61.7) | 186 | 153 (82.3) | <.001 |
| Enterobacterales | Ciprofloxacin | 1058 | 312 (29.5) | 206 | 122 (59.2) | <.001 |
| Enterobacterales | Levofloxacin | 1019 | 306 (30.0) | 160 | 90 (56.3) | <.001 |
| Enterobacterales | Meropenem | 982 | 610 (62.1) | 187 | 149 (79.7) | <.001 |
| Pseudomonas aeruginosa | Piperacillin-tazobactam | 1064 | 559 (52.5) | 197 | 150 (761) | <.001 |
| Acinetobacter baumannii | Imipenem | 784 | 367 (46.8) | 182 | 139 (76.4) | <.001 |